AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04887987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training + active PBMT
Description: Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
Study NCT04887987 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pilates training + sham PBMT
Description: Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
Study NCT04887987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training + active PBMT
Description: Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
Study NCT04887987 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Multicomponent training + sham PBMT
Description: Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
Study NCT06443099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different methods used after intramuscular injection
Description: Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
Study NCT05100446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin - high dose dual therapy
Description: Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
Study NCT05100446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pylera
Description: Eradication with Pylera, for 10 days.
Study NCT05100446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg, twice a day.
Study NCT04530864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
Study NCT05114876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent delirium-risk prevention bundle
Description: This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses.
Study NCT06390709 — intervention group
Intervention type: OTHER
Intervention: Lab Collection Only
Description: 2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
Study NCT03862924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Research Electronic Cigarette
Description: Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
Study NCT06091969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active multi-ingredient supplement (Fertility Enhancer, FE)
Description: Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
Study NCT05387564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT Documentation and Disclosure Toolkit (SCT-DD)
Description: A toolkit of implementation strategies
Study NCT05453565 — intervention group
Intervention type: OTHER
Intervention: Vasopressors
Description: A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
Study NCT05453565 — intervention group
Intervention type: OTHER
Intervention: Fluids
Description: A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
Study NCT04944966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maytenus Senegalensis
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg
Study NCT04944966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maytenus Senegalensis
Description: * Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Magnetic stimulation of the cortex
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Magnetic stimulation of the cortex
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Magnetic stimulation of the cortex
Study NCT06091969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo (Placebo; PLA)
Description: Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Stimulation
Description: Electric stimulation of the nerves
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Electric stimulation of the nerves
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Electric stimulation of the cortex
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Associative Stimulation
Description: Combined magnetic and electric stimulation of cortex and nerve, respectively
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: Combined magnetic and electric stimulation of cortex and nerve, respectively
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist
Description: Short-term immobilization of the arm
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic arm
Description: External perturbation of force field induced by robotic arm
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic arm
Description: External perturbation of force field induced by robotic arm
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervicomedullar stimulation
Description: Electric stimulation of the muscle
Study NCT05991869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Point-of-care decision support intervention
Description: PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly.
Study NCT05548387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2202
Description: Take it once per period.
Study NCT05548387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once per period.
Study NCT05548387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once per period.
Study NCT04975295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: Administered SC
Study NCT04975295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04784832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervicomedullar stimulation
Description: Electric stimulation of the muscle
Study NCT06542614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3906 capsules
Description: To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
Study NCT06542614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TQH3906 capsules
Description: Placebo without drug substance.
Study NCT04784832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Training to perform the task by actually doing the task
Study NCT04784832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental training
Description: Training to perform the task by imaging doing the task
Study NCT04784832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental training
Description: Training to perform the task by imaging doing the task
Study NCT04784832 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mental training
Description: Training to perform the task by imaging doing the task
Study NCT05419596 — intervention group
Intervention type: PROCEDURE
Intervention: Urologic Surgery
Description: Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
Study NCT05534412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: 1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails.
Study NCT05534412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support
Description: Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
Study NCT05534412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP Co-management
Description: To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated.
Study NCT05534412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Referral
Description: In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics).
Study NCT05718011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
Study NCT05718011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
Study NCT04558931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellProtect
Description: In vitro expanded and activated autologous NK cells
Study NCT04558931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
Study NCT05012020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth Remote Monitoring platform
Description: Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
Study NCT04786847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TLX591
Description: TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
Study NCT05744960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training
Description: Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
Study NCT05744960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: financial Incentive
Description: Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
Study NCT05771246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic evaluation
Description: Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
Study NCT05673057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
Description: Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.
Study NCT05038306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine WT
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
Study NCT05038306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese medicine WT
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
Study NCT06523140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boracare remote monitoring solution
Description: Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
Study NCT05212220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA-based intervention
Description: A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
Study NCT04558931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
Study NCT05212220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA-based intervention
Description: Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
Study NCT06002672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).
Description: Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
Study NCT06002672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.
Description: 100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
Study NCT05706831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinatory effect of music stimulation and neurostimulation
Description: music
Study NCT05354115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
Description: Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
Study NCT05499546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCALE EYE
Description: Polyp size measurement using the SCALE EYE functionality
Study NCT04856163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telelactation support
Description: Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
Study NCT06077409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin To Skin
Description: Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure.